1. |
Simó-Servat O, Hernández C, Simó R. Diabetic retinopathy in the context of patients with diabetes[J]. Ophthalmic Res, 2019, 62(4): 211-217. DOI: 10.1159/000499541.
|
2. |
Takino JI, Miyazaki S, Nagamine K, et al. The role of RASGRP2 in vascular endothelial cells-a mini review[J/OL]. Int J Mol Sci, 2021, 22(20): 11129[2021-10-15]. https://pubmed.ncbi.nlm.nih.gov/34681791/. DOI: 10.3390/ijms222011129.
|
3. |
Huang S, Wang J, Zhang L, et al. Ras guanine nucleotide-releasing protein-4 promotes renal inflammatory injury in type 2 diabetes mellitus[J/OL]. Metabolism, 2022, 131: 155177[2022-02-23]. https://pubmed.ncbi.nlm.nih.gov/35218794/. DOI: 10.1016/j.metabol.2022.155177.
|
4. |
Adachi R, Krilis SA, Nigrovic PA, et al. Ras guanine nucleotide-releasing protein-4 (RasGRP4) involvement in experimental arthritis and colitis[J]. J Biol Chem, 2012, 287(24): 20047-20055. DOI: 10.1074/jbc.M112.360388.
|
5. |
Suire S, Lécureuil C, Anderson KE, et al. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2/b3 and the RasGEF RasGRP4[J]. EMBO J, 2012, 31(14): 3118-3129. DOI: 10.1038/emboj.2012.167.
|
6. |
Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks[J]. Nat Protoc, 2012, 7(3): 562-578. DOI: 10.1038/nprot.2012.016.
|
7. |
Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1): 263. DOI: 10.1038/s41392-021-00658-5.
|
8. |
Spencer BG, Estevez JJ, Liu E, et al. Pericytes, inflammation, and diabetic retinopathy[J]. Inflammopharmacology, 2020, 28(3): 697-709. DOI: 10.1007/s10787-019-00647-9.
|
9. |
Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489. DOI: 10.1038/s41577-019-0165-0.
|
10. |
Sharma M, de Alba E. Structure, activation and regulation of NLRP3 and AIM2 inflammasomes[J]. Int J Mol Sci, 2021, 22(2): 872. DOI: 10.3390/ijms22020872.
|
11. |
Gritsenko A, Green JP, Brough D, et al. Mechanisms of NLRP3 priming in inflammaging and age related diseases[J]. Cytokine Growth Factor Rev, 2020, 55: 15-25. DOI: 10.1016/j.cytogfr.2020.08.003.
|
12. |
Gaidt MM, Hornung V. The NLRP3 inflammasome renders cell death pro-inflammatory[J]. J Mol Biol, 2018, 430(2): 133-141. DOI: 10.1016/j.jmb.2017.11.013.
|
13. |
Campden RI, Zhang Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation[J]. Arch Biochem Biophys, 2019, 670: 32-42. DOI: 10.1016/j.abb.2019.02.015.
|
14. |
Paik S, Kim JK, Silwal P, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation[J]. Cell Mol Immunol, 2021, 18(5): 1141-1160. DOI: 10.1038/s41423-021-00670-3.
|
15. |
Yang Y, Jiang G, Huang R, et al. Targeting the NLRP3 inflammasome in diabetic retinopathy: from pathogenesis to therapeutic strategies[J/OL]. Biochem Pharmacol, 2023, 212: 115569[2023-04-25]. https://pubmed.ncbi.nlm.nih.gov/37100255/. DOI: 10.1016/j.bcp.2023.115569.
|
16. |
Chen H, Zhang X, Liao N, et al. Enhanced expression of NLRP3 inflammasome-related inflammation in diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2018, 59(2): 978-985. DOI: 10.1167/iovs.17-22816.
|
17. |
Chai G, Liu S, Yang H, et al. NLRP3 blockade suppresses pro-inflammatory and pro-angiogenic cytokine secretion in diabetic retinopathy[J]. Diabetes Metab Syndr Obes, 2020, 13: 3047-3058. DOI: 10.2147/dmso.S264215.
|
18. |
Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy[J]. Int J Mol Sci, 2018, 19(4): 942. DOI: 10.3390/ijms19040942.
|